Navigation Links
Michael Reitermann to Head Siemens Healthcare U.S. Organization
Date:6/29/2009

Predecessor Heinrich Kolem will lead the global angiography, fluoroscopy and X-ray business

MALVERN, Pa., June 29 /PRNewswire-FirstCall/ -- Michael Reitermann has been appointed the new CEO of Siemens Healthcare's U.S. organization, effective July 1, 2009. In his new position, Reitermann will lead the marketing, sales and service functions for Siemens Healthcare in the U.S., including the medical imaging, therapy and health care information technology businesses. He will be based at the U.S. headquarters in Malvern, Pa. Reitermann succeeds Dr. Heinrich Kolem, who will assume the role of global head of Siemens Healthcare's Angiography, Fluoroscopy and X-ray business unit, based in Forchheim, Germany.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

Reitermann has enjoyed a long career with Siemens. Among other things, he worked as a senior project manager at the corporate strategies division as well as a partner in Siemens Management Consulting. Reitermann also served as vice president for sales, marketing and innovation of the Siemens Angiography, Fluoroscopy and X-ray business unit. Most recently, as CEO of Siemens Molecular Imaging (MI) Business Unit, and president of the former Nuclear Medicine division since July 2002, Reitermann was responsible for the establishment and implementation of MI's business objectives around the world.

Heinrich Kolem will take on a new challenge, assuming the role of global head of Siemens Healthcare's Angiography, Fluoroscopy and X-ray business unit. Since 2006, Kolem was the CEO of the Siemens Healthcare organization in the United States overseeing launches of innovative new imaging systems such as the SOMATOM Definition Flash, MAGNETOM Essenza, Biograph mCT, the Acuson S2000 and other novel innovations. Kolem started his Siemens career in the field of Magnetic Resonance Imaging in 1989.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is the first integrated healthcare company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care -- from prevention and early detection, to diagnosis, therapy and care. Additionally, Siemens Healthcare is the global market leader in innovative hearing instruments. The company employs around 49,000 people worldwide and operates in 130 countries. In the fiscal year 2008 (Sept. 30), Siemens Healthcare reported sales of euro 11.2 billion, orders of euro 11.8 billion, and Sector profit of euro 1.2 billion. Further information can be found by visiting http://www.siemens.com/healthcare.


'/>"/>
SOURCE Siemens Healthcare
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jillian Michaels, Americas Toughest Trainer, Announces New Line of Weight-Loss Supplements
2. Michael Jackson Get the Medical Facts Behind the Headlines at CelebrityDiagnosis.com
3. Michael Jackson Joins Tragic List of Accidental Celebrity Deaths Caused by Prescription Drugs, Says eDrugSearch.com
4. Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson
5. American Heart Association Extends Sympathy to Family of Singer Michael Jackson
6. Michael Jacksons Death Underscores the Tragedy and Impact of Sudden Cardiac Arrest
7. The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors
8. Michael E. DeBakey Journalism Award Recipients Announced
9. Michael Simmons, DMD presented a poster at the American Academy of Dental Sleep Medicine Meeting
10. The Rev. Michael J. OConnell Assumes Chairmanship of Hazelden Foundation Board of Trustees
11. Michael J. Fox Foundation Announces Launch of PD Online Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to ... available through Jet.com. , After 25 years of development, the company released its ... quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the family ... is from Southwest Nebraska where she was raised on a farm. As Diane ... is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always been ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: